STOCK TITAN

Revolution Medicines (RVMD) director sells 10,020 shares in Rule 10b5-1 tax sale

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Revolution Medicines director and officer Mark A. Goldsmith reported an open-market sale of 10,020 shares of common stock on June 16, 2026 at a weighted average price of $156.1188 per share. The transaction was executed under a pre-arranged Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy tax withholding obligations from restricted stock unit vesting.

Following this sale, Goldsmith directly holds 267,330 shares of Revolution Medicines common stock, which includes 182,938 restricted stock units and 652 shares acquired under the company’s Employee Stock Purchase Plan. He also has additional indirect holdings through family revocable trusts.

Positive

  • None.

Negative

  • None.
Insider GOLDSMITH MARK A
Role See Remarks
Sold 10,020 shs ($1.56M)
Type Security Shares Price Value
Sale Common Stock 10,020 $156.1188 $1.56M
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 267,330 shares (Direct, null); Common Stock — 594,060 shares (Indirect, Trust)
Footnotes (1)
  1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. This transaction was executed in multiple trades at prices ranging from $156.1105 to $156.8250. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Includes 182,938 restricted stock units. Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026. Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust. Held by Jonathan Goldsmith Revocable Trust. Held by Rebecca Goldsmith Revocable Trust.
Shares sold 10,020 shares Open-market sale on June 16, 2026
Weighted average sale price $156.1188 per share Open-market sale on June 16, 2026
Direct holdings after transaction 267,330 shares Common stock directly held following June 16, 2026 sale
Restricted stock units included 182,938 RSUs Included in direct holdings after transaction
ESPP shares included 652 shares Acquired under Employee Stock Purchase Plan on May 31, 2026
Trust holding example 64,424 shares Indirect common stock holding reported through a trust
Additional trust holding example 594,060 shares Another indirect common stock holding reported through a trust
Rule 10b5-1 regulatory
"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
restricted stock units financial
"to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs")"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Employee Stock Purchase Plan financial
"Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026."
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Revocable Living Trust financial
"Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GOLDSMITH MARK A

(Last)(First)(Middle)
C/O REVOLUTION MEDICINES, INC.
700 SAGINAW DRIVE

(Street)
REDWOOD CITY CALIFORNIA 94063

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/16/2026S(1)10,020D$156.1188(2)267,330(3)(4)D
Common Stock594,060ITrust(5)
Common Stock64,424ITrust(6)
Common Stock64,424ITrust(7)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.
2. This transaction was executed in multiple trades at prices ranging from $156.1105 to $156.8250. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. Includes 182,938 restricted stock units.
4. Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026.
5. Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
6. Held by Jonathan Goldsmith Revocable Trust.
7. Held by Rebecca Goldsmith Revocable Trust.
Remarks:
President and Chief Executive Officer
/s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith06/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

How many Revolution Medicines (RVMD) shares did Mark A. Goldsmith sell?

Mark A. Goldsmith sold 10,020 shares of Revolution Medicines common stock. The sale occurred on June 16, 2026 at a weighted average price of $156.1188 per share in an open-market transaction disclosed in a Form 4 filing.

At what price did Mark A. Goldsmith’s RVMD share sale occur?

The reported weighted average sale price was $156.1188 per share. The transaction was executed in multiple trades within a price range from $156.1105 to $156.8250, with the weighted average figure disclosed in the filing as the summary transaction price.

Why did Mark A. Goldsmith sell RVMD shares according to the Form 4?

The sale was made under a Rule 10b5-1 instruction letter adopted on May 31, 2023. According to the filing, it was specifically designed to satisfy Goldsmith’s tax withholding obligations arising from the vesting of restricted stock units after July 15, 2023.

How many Revolution Medicines (RVMD) shares does Mark A. Goldsmith hold after the sale?

After the reported sale, Goldsmith directly holds 267,330 shares of Revolution Medicines common stock. This direct position includes 182,938 restricted stock units and 652 shares acquired under the company’s Employee Stock Purchase Plan, as detailed in the Form 4 footnotes.

What indirect RVMD holdings does Mark A. Goldsmith report through trusts?

The filing lists indirect holdings through revocable trusts, including shares held by the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust, the Jonathan Goldsmith Revocable Trust, and the Rebecca Goldsmith Revocable Trust, reflecting additional exposure held in trust form.

How are restricted stock units reflected in Mark A. Goldsmith’s RVMD holdings?

Goldsmith’s direct holdings include 182,938 restricted stock units. These RSUs represent rights to receive shares of Revolution Medicines common stock in the future, and are counted within the 267,330 directly held shares disclosed after the reported sale transaction.

Did Mark A. Goldsmith acquire RVMD shares through an Employee Stock Purchase Plan?

Yes. The filing notes that his holdings include 652 shares acquired under Revolution Medicines’ Employee Stock Purchase Plan. These shares were purchased on May 31, 2026 and are part of his reported direct ownership following the June 16, 2026 sale.